sangamo-041918-8024-rt2

Sangamo

4 June 2018Americas

ZFN: a rival to CRISPR

While CRISPR gene-editing and the battle over its patents continue to dominate headlines, a lesser known contender is making a name for itself, partly thanks to the drive of one company.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

WATCH: Enabling success—mastering s112 in the new era of life sciences patents

US firm Brownstein nabs five from Crowell ‘at pivotal moment’

American Regent secures rare PI win in Hatch-Waxman dispute

WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US

Explainer: ARIPO’s role in Plant Variety Protection

J&J sues over schizophrenia drug generic following patent victory

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’